prasugrel Archivi - Journal Map

Possiamo dare l’addio all’ASA nel trattamento della sindrome coronarica acuta?

Marzo 26, 2024

Una serie di studi recenti ha dimostrato la sicurezza di strategie farmacologiche basate su breve durata di doppia terapia antipiastrinica (DAPT) dopo sindrome coronarica acuta (ACS) e successivo trattamento con monoterapia basata su inibitore del recettore piastrinico P2Y12. . Tuttavia nessuno studio ha sperimentato una strategia “ASA”, basata su una monoterapia immediata con un inibitore del recettore P2Y12, senza una fase iniziale di DAPT.

Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study

Febbraio 13, 2024

Aims: Based on recent clinical data, the 2020 ESC guidelines on non-ST-elevation acute coronary syndrome (NSTE-ACS) suggest to tailor antithrombotic strategy on individual thrombotic risk. Nonetheless, prevalence and prognostic impact of the high thrombotic risk (HTR) criteria proposed are yet to be described. In this analysis from the PROMETHEUS registry, we assessed prevalence and prognostic impact of HTR, defined according to the 2020 ESC NSTE-ACS guidelines, and if the benefits associated with prasugrel vs. clopidogrel vary with thrombotic risk.

Safety and efficacy of different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multicentre study.

Febbraio 1, 2023

Aims: To establish the safety and efficacy of different dual antiplatelet therapy (DAPT) combinations in patients with acute coronary syndrome (ACS) according to their baseline ischaemic and bleeding risk estimated with a machine learning derived model [machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE) score].

Terapia antipiastrinica guidata o standard per i pazienti sottoposti a PCI? Una metanalisi.

Dicembre 10, 2021

Inquadramento I primi studi che hanno valutato il ruolo dei test di funzione piastrinica, e dei test genetici per ottimizzare la scelta della terapia antipiastrinica

Ticagrelor and prasugrel in acute coronary syndrome: a single-arm crossover platelet reactivity study.

Agosto 23, 2021

Il riscontro di elevata reattività piastrinica residua (HRPR) nonostante trattamento con i potenti inibitori del recettore P2Y12 (ticagrelor e prasugrel) si verifica in una percentuale

Quale inibitore del recettore piastrinico P2Y12 utilizzare nello STEMI. Prasugrel o Ticagrelor?

Giugno 1, 2021

Inquadramento Ticagrelor e prasugrel sono due potenti inibitori del recettore P2Y12 che nei rispettivi trial di confronto con clopidogrel, in pazienti con sindrome coronarica acuta

Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome. Network Meta-Analysis of 52.816 Patients From 12 Randomized Trials

Marzo 22, 2021

New randomized, controlled trials have become available on oral P2Y12 inhibitors in acute coronary syndrome. We aimed to evaluate current evidence comparing the efficacy and safety profile of prasugrel, ticagrelor, and clopidogrel in acute coronary syndrome by a meta-analysis of randomized controlled trials.

Quick Survey 08

Febbraio 22, 2021

Un ulteriore aspetto controverso delle “2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation” è la raccomandazione (classe IIa, evidenza B) che prasugrel sia da preferire a ticagrelor quando i pazienti vengano sottoposti a procedura di PCI.

Cookie	Durata	Descrizione
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Possiamo dare l’addio all’ASA nel trattamento della sindrome coronarica acuta?

Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study

Safety and efficacy of different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multicentre study.

Terapia antipiastrinica guidata o standard per i pazienti sottoposti a PCI? Una metanalisi.

Ticagrelor and prasugrel in acute coronary syndrome: a single-arm crossover platelet reactivity study.

Quale inibitore del recettore piastrinico P2Y12 utilizzare nello STEMI. Prasugrel o Ticagrelor?

Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome. Network Meta-Analysis of 52.816 Patients From 12 Randomized Trials

Quick Survey 08

“Falsi positivi” al test da sforzo: veri “falsi” o falsi “falsi”?

Atrioventricular Block: Does This Patient Require a Pacemaker?

Uso di apixaban nei pazienti con nefropatia cronica avanzata: quale dosaggio?

Categorie